Di-or triaza-spiro [4,5] decane derivatives

Compounds of the general formula I ##STR92## wherein R.sup.1 is C.sub.6 -cycloalkyl which is substituted by lower alkyl or --C(O)O-lower alkyl; C.sub.7-10 -cycloalkyl, which is unsubstituted or substituted by lower alkyl or --C(O)O-lower alkyl; decahydro-naphthalen-1-yl; decahydro-naphthalen-2-yl; indan-1-yl or indan-2-yl, which is unsubstituted or substituted by lower alkyl; decahydro-azulen-2-yl; bicyclo[6.2.0]dec-9-yl; acenaphthen-1-yl; 2,3-dihydro-1H-phenalen-1-yl; 2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl or octahydro-inden-2-yl; R.sup.2 is hydrogen; lower alkyl; .dbd.O or phenyl, which is unsubstituted or substituted by lower alkyl, halogen or alkoxy; .sup.A is cyclohexyl or phenyl, which is unsubstituted or substituted by lower alkyl, halogen or alkoxy; X is --CH(OH)--; --C(O)--; --CHR.sup.3 --; --CR.sup.3.dbd.; --O--; --S--; --CH(COOR.sup.4)-- or --C(COOR.sup.4).dbd.; Y is --CH.sub.2 --; --CH.dbd.; --CH(COOR.sup.4)--, --C(COOR.sup.4).dbd.; or --C(CN)--; R.sup.3 is hydrogen or lower alkoxy; R.sup.4 is lower alkyl, cycloalkyl, phenyl, or benzyl and either a or b is optionally an additional bond, racemic mixtures and their corresponding enantiomers and pharmaceutically acceptable acid addition salts thereof.

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I ##STR93## wherein R.sup.1 is C.sub.6 -cycloalkyl which is substituted by lower alkyl or --C(O)O-lower alkyl; C.sub.7-10 -cycloalkyl, which is unsubstituted or substituted by lower alkyl or --C(O)O-lower alkyl; decahydro-naphthalen-1-yl; decahydro-naphthalen-2-yl; indan-1-yl or indan-2-yl, which is unsubstituted or substituted by lower alkyl; decahydro-azulen-2-yl; bicyclo[6.2.0]dec-9-yl; acenaphthen-1-yl; 2,3-dihydro-1H-phenalen-1-yl; 2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl or octahydro-inden-2-yl; R.sup.2 is hydrogen; lower alkyl; .dbd.O or phenyl, which is unsubstituted or substituted by lower alkyl, halogen or alkoxy; .sup.A is cyclohexyl or phenyl, which is unsubstituted or substituted by lower alkyl, halogen or alkoxy; X is --CH(OH)--; --C(O)--; --CHR.sup.3 --; --CR.sup.3.dbd.; --O--; --S--; --CH(COOR.sup.4)-- or --C(COOR.sup.4).dbd.; Y is --CH.sub.2 --; --CH.dbd.; --CH(COOR.sup.4)--, --C(COOR.sup.4).dbd.; or --C(CN)--; R.sup.3 is hydrogen or lower alkoxy; R.sup.4 is lower alkyl, cycloalkyl, phenyl, or benzyl and either a or b is optionally an additional bond, as well as pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.

A method of treating disorders in mammals related to the orphanin FQ receptor selected from the group consisting of anxiety, stress, depression, trauma, Alzheimer's mediated memory loss, epilepsy, arterial blood pressure disorders, obesity, acute pain, chronic pain, Na+ excretion, control of water balance, and symptoms associated with drug withdrawal comprising administering to said mammal a therapeutically effective amount for treating said disorder of a compound of formula I ##STR94## wherein R.sup.1 is C.sub.6-10 -cycloalkyl, which is unsubstituted or substituted by lower alkyl or --C(O)O-lower alkyl; decahydro-naphthalen-1-yl; decahydro-naphthalen-2-yl; indan-1-yl or indan-2-yl, which is unsubstituted or substituted by lower alkyl; decahydro-azulen-2-yl; bicyclo[6.2.0]dec-9-yl; acenaphthen-1-yl; 2,3-dihydro-1H-phenalen-1-yl; 2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl or octahydro-inden-2-yl; R.sup.2 is hydrogen; lower alkyl; .dbd.O or phenyl, which is unsubstituted or substituted by lower alkyl, halogen or alkoxy; .sup.A is cyclohexyl or phenyl, which is unsubstituted or substituted by lower alkyl, halogen or alkoxy; X is --CH(OH)--; --C(O)--; --CHR.sup.3 --; --CR.sup.3.dbd.; --O--; --S--; --CH(COOR.sup.4)-- or --C(COOR.sup.4).dbd.; Y is --CH.sub.2 --; --CH.dbd.; --CH(COOR.sup.4)--, --C(COOR.sup.4).dbd.; or --C(CN)--; R.sup.3 is hydrogen or lower alkoxy; R.sup.4 is lower alkyl, cycloalkyl, phenyl, or benzyl and either a or b is optionally an additional bond, as well as pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.